Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with GuadecitabineCasey L. O’Connell, Kirsten Grønbæk, Andreas Due Ørskov et al.|Clinical Cancer Research|2022Cited by 27